Universiteit Gent

Vib Vzw

Research Corporation Technologies, Inc.

Flanders Interuniversity Institute for Biotechnology

Other

Vlaams Interubiversitair Instituut Voor Biotechnologie Vzw

Nico L M Callewaert

Roland Henri Contreras

Steven C J Geysens

Vladimir Kaigorodov

Wouter Vervecken

Steven Geysens

Francis Santens

Leander Meuris

Vervecken Wouter

Karen De Pourcq

Toon Laeremans

Jan Steyaert

Els Pardon

Bram Laukens

Kristof Vandewalle

Katrien Claes

Tom Raes

Dieter Vanderschaeghe

The disclosure relates cells or cellular systems that express both a membrane protein and a binding domain directed to the membrane protein. Also, methods are provided that use such cells or cellular systems to produce higher amounts of the membrane proteins. Further, the cells or cellular systems can be used as tools for the structural and functional characterization of membrane proteins, as well as for screening and drug discovery efforts targeting membrane proteins.

Tools and methods for expression of membrane proteins

The present application relates to the field of glyco-engineering, more specifically to glyco-engineering of Fc-containing molecules, such as antibodies. It is shown herein that Fc-containing molecules with a specific glycosylation pattern have a considerably longer circulating half-life in vivo, without having an altered binding affinity for their respective antigen. This has therapeutic implications in reducing the frequency with which these molecules need to be administered, without affecting therapeutic efficacy. Also, cells are provided that can produce the Fc molecules with the desired glycosylation pattern.

Cells producing Fc containing molecules having altered glycosylation patterns and methods and use thereof

The application discloses methods, kits and a novel biomarker to detect and/or to prognose inflammation in patients. The diagnostic test is based on measuring the ratio of galactosylated and non-galactosylated specific N-glycans as obtained by enzymatic treatment of the total mixture of proteins present in a body fluid such as blood, serum or plasma.

Means and methods for monitoring inflammation

The disclosure relates to the field of glyco-engineering, more specifically, to eukaryotic cells wherein both an endoglucosaminidase and a glycoprotein are present. These cells can be used to deglycosylate or partly deglycosylate the (exogenous) glycoprotein, in particular, without the need for adding an extra enzyme. Methods are also provided for the application of these cells in protein production. According to one specific aspect, the eukaryotic cells are glyco-engineered yeast cells in which, additionally, at least one exogenous enzyme needed for complex glycosylation is present, e.g., allowing easier separation of differentially glycosylated glycoproteins.

Cells producing glycoproteins having altered glycosylation patterns and method and use thereof

The present application relates to the field of glyco-engineering, more specifically to glycosylation-engineered fungal cells, more specifically glycosylation-engineered yeast cells, optimized to produce highly homogenous forms of complex N-glycans on recombinant proteins. The invention specifically relates to methods to obtain pharmaceutical compositions comprising recombinant glycoproteins which have homogenous forms of complex N-glycans. In addition, the invention relates to novel pharmaceutical compositions which result from the methods of the invention.

Means and methods for generating complex glycans derived from fungal engineered hosts

Cells producing Fc-containing molecules having altered glycosylation patterns and methods and use thereof

The present invention provides genetically engineered strains of methylotrophic yeast includingand especiallycapable of producing proteins with reduced or modified glycosylation. Methods of producing glycoproteins with reduced and/or modified glycosylation using such genetically engineered strains ofare also provided. Vectors, which comprise coding sequences for &#x3b1;-1,2-mannosidase I, glucosidase II, GlcNAc-tranferase I and mannosidase II or comprising OCH1 disrupting sequence, for transforming methylotrophic yeasts are contemplated by the present invention. Kit for providing the comtemplated vectors are also included in this invention.

Protein glycosylation modification in methylotrophic yeast

The present application relates to the field of glyco-engineering, more specifically to eukaryotic cells wherein both an endoglucosaminidase and a glycoprotein are present. These cells can be used to deglycosylate or partly deglycosylate the (exogenous) glycoprotein, in particular without the need for adding an extra enzyme. Methods are also provided for the application of these cells in protein production. According to one specific aspect, the eukaryotic cells and methods are glyco-engineered yeast cells in which additionally at least one exogenous enzyme needed for complex glycosylation is present, e.g. allowing easier separation of differentially glycosylated glycoproteins.

The present invention provides genetically engineered strains ofcapable of producing proteins with reduced glycosylation. In particular, the genetically engineered strains of the present invention are capable of expressing either or both of an &#x3b1;-1,2-mannosidase and glucosidase II. The genetically engineered strains of the present invention can be further modified such that the OCH1 gene is disrupted. Methods of producing glycoproteins with reduced glycosylation using such genetically engineered stains ofare also provided.

The present invention relates to methods and genetically engineered methylotrophic yeast strains for producing glycoproteins with mammalian-like glycosylation. The present invention also relates to vectors useful for generating methylotrophic yeast strains capable of producing glycoproteins with mammalian-like glycosylation. Glycoproteins produced from the genetically engineered methylotrophic yeast strains are also provided.

Modification of protein glycosylation in methylotrophic yeast

The invention provides methods and kits to detect liver cirrhosis in mammals. The diagnostic test is based on the profiling and identification of diagnostic carbohydrates present in a body fluid such as blood serum.

Marker for measuring liver cirrhosis

The present invention provides genetically engineered strains of Pichia capable of producing proteins with reduced glycosylation. In particular, the genetically engineered strains of the present invention are capable of expressing either or both of an (&agr;-1,2-mannosidase and glucosidase II. The genetically engineered strains of the present invention can be further modified such that the OCH1 gene is disrupted. Methods of producing glycoproteins with reduced glycosylation using such genetically engineered stains of Pichia are also provided.

Growing community of inventors

Lichtervelde, Belgium

Nico L M Callewaert